European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. A dozen consumer groups and trade ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ ...

Catalent is an attractive buyout target for Novo Holdings — which owns 77% of the voting shares in the drugmaker — because it is currently a subcontractor that helps manufacture Wegovy ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

A Catalent spokesperson reiterated the company's position on the deal in a statement on Friday to Reuters in response to the letter: "Novo Holdings’ pending acquisition of Catalent will further ...

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...